Table 1.
Characteristics of patients whose samples were used for the evaluation of enzymatic immunoassays.
| HEV-A (n = 59)∗ | |
|---|---|
| Median age in years (interquartile range) | 59 (51–66) |
| Male:female (number of patients) | 40:19 |
| Immunosuppressive conditions (n, %) | 11 (18.6) |
| Organ transplant | 9 |
| Haematological malignancy | 2 |
| Infecting genotype (n, %) | |
| HEV-A genotype 1 | 1 (1.7) |
| HEV-A genotype 3 | 6 (10.2) |
| HEV-A genotype 4 | 47 (79.7) |
| HEV-A; genotype unknown† | 5 (8.4) |
| HEV-C1 patients (n = 16)∗ | |
| Median age in years (interquartile range) | 72 (60.5–79) |
| Male:female (number of patients) | 13:3 |
| Immunosuppressive conditions (n, %) | 8 (50) |
| Organ transplant | 6 |
| Haematological malignancy | 1 |
| Advanced HIV infection | 1 |
HEV-A, Paslahepevirus balayani; HEV-C1, Rocahepevirus ratti; HIV, human immunodeficiency virus.
∗
Four HEV-A and two HEV-C1 samples were excluded from final evaluation panel because optical densities were < background thresholds.
†
HEV-A RT-PCR positive, sequencing not possible because of low viral load.